Form 4: Protara Therapeutics Director Acquires Stock Options

Michael Edward Solomon, a Director at Protara Therapeutics, Inc., acquired 31,000 stock options with an exercise price of $3.94.

Summary

• Michael Edward Solomon, a Director of Protara Therapeutics, Inc., was granted 31,000 stock options on June 15, 2026.
• The stock options have an exercise price of $3.94 per share.
• These options are set to vest in full on the first anniversary of the grant date, provided Mr. Solomon remains a director, or upon a Change of Control.
• The options have an expiration date of June 14, 2036.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, indicating standard executive compensation practices and alignment of director interests with the company's stock performance.

Positives

• Director acquisition of stock options aligns with management's commitment to the company's future performance.
• The vesting schedule incentivizes continued service and long-term value creation.
• The grant of options suggests confidence in the company's growth prospects.

Risks

• The value of the stock options is contingent on the future stock price performance of Protara Therapeutics.
• If the company does not achieve its strategic goals, the options may not become significantly valuable.

Future Outlook

The grant of stock options to a director suggests a positive outlook on the company's future stock performance, as the value of these options is directly tied to it.

Industry Context

StockSavvy.ai notes that the issuance of stock options to directors is a common practice in the biotechnology and pharmaceutical sectors, serving as a key incentive for leadership to align their interests with shareholders and drive long-term company value.

Stakeholder Impact

• Shareholders: The alignment of director compensation with stock performance can be viewed positively, potentially leading to increased focus on shareholder value.
• Management: The stock options provide a financial incentive for continued service and performance.
• Employees: While not directly impacted, the alignment of leadership can indirectly benefit the company's overall direction and success.

Next Steps

• Director Michael Edward Solomon will continue to serve on the board.
• The stock options will vest on June 15, 2027, or upon a Change of Control.
• The stock options will expire on June 14, 2036.

Key Dates

Keywords

Protara Therapeutics, TARA, Form 4, Stock Options, Director, Beneficial Ownership, SEC Filing, Equity Award